The Impact of Systemic Factors on Clinical Response to Ranibizumab for Diabetic Macular Edema

To evaluate the effect of systemic factors on best-corrected visual acuity (BCVA) achieved with ranibizumab (Lucentis; Genentech, Inc, South San Francisco, CA) for treatment of diabetic macular edema (DME) in the RIDE and RISE phase 3 studies.Exploratory, post hoc analysis of 2 randomized, double-masked, sham-injection controlled studies.Adults with DME, BCVA of 20/40 to 20/320 Snellen equivalent, and central foveal thickness of 275 μm or...